BiotechTube

Placebo + iptacopan

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

C3G

Conditions

C3G

Trial Timeline

Jul 28, 2021 → Jan 29, 2027

NCT ID
NCT04817618

About Placebo + iptacopan

Placebo + iptacopan is a phase 3 stage product being developed by Novartis for C3G. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04817618. Target conditions include C3G.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05755386Phase 3Recruiting
NCT04817618Phase 3Recruiting

Competing Products

6 competing products in C3G

See all competitors
ProductCompanyStageHype Score
IptacopanNovartisPre-clinical
23
Avacopan + Avacopan Matching PlaceboAmgenPhase 2
51
PegcetacoplanApellis PharmaceuticalsPhase 3
72
PegcetacoplanApellis PharmaceuticalsPhase 2
47
PegcetacoplanApellis PharmaceuticalsPhase 3
72
PegcetacoplanApellis PharmaceuticalsPre-clinical
18

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85